Company Overview of HUYA Bioscience International, LLC
HUYA Bioscience International, LLC engages in identifying and licensing pre-clinical and clinical stage compounds in China. It engages in accelerating the development of biopharmaceutical product opportunities originating in China. The company offers HBI-8000, a histone deacetylases inhibitors for cancer; HBI-3000, a multi-ion channel blocker for the treatment of arrhythmia; and HBI-3802, a small molecule for improving heart function, as well as stimulates cardiac stem cell differentiation into functional cardiomyocytes, and replaces and remodels dead myocardium with new functional tissues. The company has strategic alliances with China Wuqing Development Area and Korea Drug Development Fund...
12531 High Bluff Drive
San Diego, CA 92130
Founded in 2004
Key Executives for HUYA Bioscience International, LLC
Founder and Executive Chairman
Chief Technology Officer and Chief Operating Officer of Asia
Chief Scientific Officer and Executive Vice President
Head of Therapeutics China
Compensation as of Fiscal Year 2016.
HUYA Bioscience International, LLC Key Developments
Huya Presents at ChinaBio Partnering Forum 2016, May-19-2016 03:30 PM
May 15 16
Huya Presents at ChinaBio Partnering Forum 2016, May-19-2016 03:30 PM. Venue: Suzhou, China.
HUYA Bioscience International Announces the Appointment of John Ratliff as President and CEO
Mar 23 16
HUYA Bioscience International, announced the appointment of John Ratliff as President and CEO. This appointment is part of the company's long term growth plan. Dr. Mireille Gillings, who founded the company, continues as Executive Chair of its Board of Directors. John Ratliff brings over 30 years of experience in the biopharmaceutical and information technology industries.
HUYA Bioscience International (China) Enters into Licensing Agreement with Fudan University
Mar 16 16
HUYA Bioscience International (China) has signed an exclusive licensing agreement with China's Fudan University for rights in China to several novel immuno-oncology candidates. Under the agreement, HUYA plans to advance into clinical testing of novel inhibitors of indoleamine 2,3-dioxygenase (IDO) developed by Fudan University scientists. In addition, HUYA also aims to proceed with ongoing development of its own novel histone deacetylase (HDAC) inhibitor HBI-8000. Financial details were not disclosed. The agreement will expand HUYA's immuno-oncology platform and potentially allow for the combination of other treatments. Huya has already entered into a licensing and development agreement with Eisai (Japan) for HBI-8000 in several Asian countries, potentially affording rapid market exposure for combination therapies. The partnership with Fudan University is also expected to leverage HUYA's experience in navigating market access.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries